Developer docs
API playgroundTry for free, no card

Search company profiles

Metsera

Full company profile

uuid000005h

Namestring
Metsera
Legal namestring
Metsera
Websiteurl
metsera.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Metsera was a New York-based clinical-stage biotechnology company founded in April 2024 that developed oral and injectable hormone therapies for obesity and related metabolic diseases. Its core technology centered on an ultra-long-acting injectable peptide platform designed to enable monthly dosing of GLP-1 receptor agonists, differentiating from the weekly-injection regimens marketed by Eli Lilly (Zepbound) and Novo Nordisk (Wegovy). The pipeline comprised four novel incretin and amylin programs, headlined by berobenatide (PF'3944), a monthly GLP-1 receptor agonist in Phase III development that demonstrated up to 15.9% body weight reduction at 32 weeks and 14.9% at 60 weeks in clinical trials, with first approvals targeted for 2028. PF'3944 (MET-097i), in Phase IIb, showed 12.3% placebo-adjusted weight loss at 28 weeks with weekly-to-monthly dosing transition, and amylin programs expanded the franchise beyond GLP-1 monotherapy.

Metsera's business model was R&D-driven rather than revenue-generating. The company launched with a $290 million financing led by ARCH Venture Partners and Population Health Partners in April 2024, followed by a $215 million round in November 2024 led by Venrock Healthcare Capital Partners and Wellington Management, with participation from SoftBank, Fidelity, Google Ventures, RA Capital, and others. There were no commercial customers, no product pricing, and no disclosed revenue; investor exit was pursued through strategic M&A. In November 2025, Pfizer acquired Metsera for approximately $7 billion upfront and up to $10 billion with contingent value rights, outbidding Novo Nordisk in a competitive auction. Post-acquisition, Metsera operates as a wholly-owned subsidiary of Pfizer, with its assets absorbed into Pfizer's obesity and metabolic disease franchise, including plans for approximately 20 pivotal clinical trial starts in 2026 across the Metsera portfolio.

Short descriptiontext

Metsera was a clinical-stage biotech that developed ultra-long-acting injectable peptide therapies, including monthly GLP-1 agonist berobenatide, for obesity and metabolic diseases. Founded April 2024, it was acquired by Pfizer in November 2025 for up to $10 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
obesity therapeutics, GLP-1 receptor agonists, amylin analogs, metabolic disease drugs, peptide drug development
Industry2 codes
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKADAN
Endocrine Hypertension & Neuroendocrine Disorders
Product category
Obesity Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1R&D Pipeline Development
TypeLicensing Royalties
Description

Pre-acquisition, Metsera was a clinical-stage biotech company developing obesity and metabolic disease medicines. The company raised $290 million at launch and was acquired by Pfizer in 2025 for approximately $10 billion (including contingent value rights), representing the primary exit mechanism for investors.

thepharmaletter.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Metsera is a clinical-stage biopharmaceutical company developing a portfolio of novel injectable and oral hormone-based therapies (GLP-1 receptor agonists and amylin analogs) for obesity and metabolic diseases. Its pipeline includes late-stage candidates aimed at next-generation obesity treatment through ultra-long-acting peptides and oral formulations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 15.9% body weight reduction at 32 weeks with monthly berobenatide dosing
+2 more records
Product overview1 text field

Metsera was a clinical-stage biotechnology company focused on obesity and metabolic disease medicines. The company was acquired by Pfizer in November 2025 for approximately $10 billion. Metsera's key product was berobenatide (PF'3944), a GLP-1 receptor agonist with monthly dosing, along with other incretin and amylin programs. These assets are now part of Pfizer's obesity pipeline with potential approvals targeted for 2028.

Product and service5 records
1Berubenatide (MET-002)
CategoryObesity Therapeutics
Description

An ultra-long-acting GLP-1 receptor agonist developed for once-monthly or less frequent dosing in adults with obesity and overweight; in Phase III clinical development.

2MET-097i (PF-3944)
CategoryObesity Therapeutics
Description

A Phase II GLP-1 receptor agonist for obesity and overweight indications with the goal of differentiated dosing or efficacy profile.

3MET-233i
CategoryObesity Therapeutics
Description

A Phase I amylin analog designed as a hormone therapy for obesity and metabolic disease, intended to be used alone or in combination with GLP-1 agents.

4Amylin program pipeline
CategoryObesity Therapeutics
Description

A broader pipeline of amylin-based peptide candidates for obesity and metabolic disease, complementing the GLP-1 franchise.

5Ultra-long-acting GLP-1 platform
CategoryDrug Discovery Platform
Description

A proprietary peptide engineering platform enabling ultra-long-acting GLP-1 receptor agonists with extended dosing intervals.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing VK2735, a dual GLP-1/GIP agonist for obesity in Phase 2/3 development. Highly comparable as a small-cap, clinical-stage obesity-focused biotech with novel incretin assets.

TypeBroad incumbent
Description

Developer and commercializer of tirzepatide (Zepbound/Mounjaro), the leading GLP-1/GIP obesity therapy. Direct competitor to Metsera's berobenatide in the obesity indication and the dominant incumbent in the GLP-1 space.

TypeBroad incumbent
Description

Maker of semaglutide (Wegovy/Ozempic), the foundational GLP-1 obesity franchise. Direct competitor to berobenatide and the other bidder in the Pfizer-Metsera acquisition auction.

TypeEmerging player
Description

Clinical-stage biotech developing oral small-molecule GLP-1 agonists (GSBR-1290) for obesity and diabetes. Comparable as an emerging obesity-focused biotech with differentiated mechanism (oral vs. injectable) addressing adherence.

TypeBroad incumbent
Description

Large biopharma developing MariTide (AMG 133), a GLP-1/amylin combination for obesity in Phase 3. Directly comparable as a major biopharma with late-stage obesity pipeline assets.

TypeEmerging player
Description

Clinical-stage biotech developing petrelintide (amylin analog) for obesity, with major partnership with Boehringer Ingelheim. Comparable through its amylin-focused obesity pipeline, mirroring Metsera's amylin program strategy.

TypeEmerging player
Description

Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity in Phase 2. Comparable as a smaller-cap, clinical-stage obesity biotech pursuing differentiated incretin mechanisms.

TypeBroad incumbent
Description

Large biopharma with a growing obesity pipeline including oral GLP-1 candidates and partnerships (e.g., Eccogene). Comparable as a major pharma making strategic entry into the obesity/metabolic disease space.

TypeBroad incumbent
Description

Large biopharma with an emerging obesity pipeline (e.g., CT-388 partnership with Carmot). Comparable as a major incumbent seeking differentiated entry into the obesity market similar to Pfizer's Metsera strategy.

TypeEmerging player
Description

Clinical-stage biotech developing incretin-based obesity therapies (acquired by Roche in 2024). Comparable as a clinical-stage biotech with differentiated GLP-1 assets that was acquired by a major pharma for its obesity pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Metsera

Obesity Therapeuticsmetsera.com

Metsera was a clinical-stage biotech that developed ultra-long-acting injectable peptide therapies, including monthly GLP-1 agonist berobenatide, for obesity and metabolic diseases. Founded April 2024, it was acquired by Pfizer in November 2025 for up to $10 billion.

What Metsera does

Metsera was a New York-based clinical-stage biotechnology company founded in April 2024 that developed oral and injectable hormone therapies for obesity and related metabolic diseases. Its core technology centered on an ultra-long-acting injectable peptide platform designed to enable monthly dosing of GLP-1 receptor agonists, differentiating from the weekly-injection regimens marketed by Eli Lilly (Zepbound) and Novo Nordisk (Wegovy). The pipeline comprised four novel incretin and amylin programs, headlined by berobenatide (PF'3944), a monthly GLP-1 receptor agonist in Phase III development that demonstrated up to 15.9% body weight reduction at 32 weeks and 14.9% at 60 weeks in clinical trials, with first approvals targeted for 2028. PF'3944 (MET-097i), in Phase IIb, showed 12.3% placebo-adjusted weight loss at 28 weeks with weekly-to-monthly dosing transition, and amylin programs expanded the franchise beyond GLP-1 monotherapy.

Metsera's business model was R&D-driven rather than revenue-generating. The company launched with a $290 million financing led by ARCH Venture Partners and Population Health Partners in April 2024, followed by a $215 million round in November 2024 led by Venrock Healthcare Capital Partners and Wellington Management, with participation from SoftBank, Fidelity, Google Ventures, RA Capital, and others. There were no commercial customers, no product pricing, and no disclosed revenue; investor exit was pursued through strategic M&A. In November 2025, Pfizer acquired Metsera for approximately $7 billion upfront and up to $10 billion with contingent value rights, outbidding Novo Nordisk in a competitive auction. Post-acquisition, Metsera operates as a wholly-owned subsidiary of Pfizer, with its assets absorbed into Pfizer's obesity and metabolic disease franchise, including plans for approximately 20 pivotal clinical trial starts in 2026 across the Metsera portfolio.

Metsera firmographics

Firmographics
Name
Metsera
Legal name
Metsera
Website
https://metsera.com
Company type
Private
Founded year
2024
Operating status
Acquired
Headcount range
51–100 employees
Short description
Metsera was a clinical-stage biotech that developed ultra-long-acting injectable peptide therapies, including monthly GLP-1 agonist berobenatide, for obesity and metabolic diseases. Founded April 2024, it was acquired by Pfizer in November 2025 for up to $10 billion.
Ownership category
akta.pro rank

Metsera industry classification

Industry
Product category
Obesity Therapeutics
akta.pro industry
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKADAN
Endocrine Hypertension & Neuroendocrine Disorders

Keywords

  • Obesity therapeutics
  • GLP-1 receptor agonists
  • Amylin analogs
  • Metabolic disease drugs
  • Peptide drug development

Where Metsera is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Metsera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Revenue model

  1. R&D Pipeline Development: Pre-acquisition, Metsera was a clinical-stage biotech company developing obesity and metabolic disease medicines. The company raised $290 million at launch and was acquired by Pfizer in 2025 for approximately $10 billion (including contingent value rights), representing the primary exit mechanism for investors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Metsera product offering

Product offering

Core offering

Metsera is a clinical-stage biopharmaceutical company developing a portfolio of novel injectable and oral hormone-based therapies (GLP-1 receptor agonists and amylin analogs) for obesity and metabolic diseases. Its pipeline includes late-stage candidates aimed at next-generation obesity treatment through ultra-long-acting peptides and oral formulations.

Product overview

Metsera was a clinical-stage biotechnology company focused on obesity and metabolic disease medicines. The company was acquired by Pfizer in November 2025 for approximately $10 billion. Metsera's key product was berobenatide (PF'3944), a GLP-1 receptor agonist with monthly dosing, along with other incretin and amylin programs. These assets are now part of Pfizer's obesity pipeline with potential approvals targeted for 2028.

Differentiator

Problem solved

Functional benefit

Products and services

  • Berubenatide (MET-002) An ultra-long-acting GLP-1 receptor agonist developed for once-monthly or less frequent dosing in adults with obesity and overweight; in Phase III clinical development.
  • MET-097i (PF-3944) A Phase II GLP-1 receptor agonist for obesity and overweight indications with the goal of differentiated dosing or efficacy profile.
  • MET-233i A Phase I amylin analog designed as a hormone therapy for obesity and metabolic disease, intended to be used alone or in combination with GLP-1 agents.
  • Amylin program pipeline A broader pipeline of amylin-based peptide candidates for obesity and metabolic disease, complementing the GLP-1 franchise.
  • Ultra-long-acting GLP-1 platform A proprietary peptide engineering platform enabling ultra-long-acting GLP-1 receptor agonists with extended dosing intervals.

Quantifiable outcome

  • 15.9% body weight reduction at 32 weeks with monthly berobenatide dosing
  • +2 more outcomes

Companies that use Metsera

Customer profile

Named customers1 record

Segments2 records

Metsera technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Metsera partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Metsera competitors and assessment

Company assessment

Direct peers

  • Viking Therapeutics: Clinical-stage biotech developing VK2735, a dual GLP-1/GIP agonist for obesity in Phase 2/3 development. Highly comparable as a small-cap, clinical-stage obesity-focused biotech with novel incretin assets.

Broad incumbents

  • Eli Lilly: Developer and commercializer of tirzepatide (Zepbound/Mounjaro), the leading GLP-1/GIP obesity therapy. Direct competitor to Metsera's berobenatide in the obesity indication and the dominant incumbent in the GLP-1 space.
  • Novo Nordisk: Maker of semaglutide (Wegovy/Ozempic), the foundational GLP-1 obesity franchise. Direct competitor to berobenatide and the other bidder in the Pfizer-Metsera acquisition auction.
  • Amgen: Large biopharma developing MariTide (AMG 133), a GLP-1/amylin combination for obesity in Phase 3. Directly comparable as a major biopharma with late-stage obesity pipeline assets.
  • AstraZeneca: Large biopharma with a growing obesity pipeline including oral GLP-1 candidates and partnerships (e.g., Eccogene). Comparable as a major pharma making strategic entry into the obesity/metabolic disease space.
  • Roche: Large biopharma with an emerging obesity pipeline (e.g., CT-388 partnership with Carmot). Comparable as a major incumbent seeking differentiated entry into the obesity market similar to Pfizer's Metsera strategy.

Emerging players

  • Structure Therapeutics: Clinical-stage biotech developing oral small-molecule GLP-1 agonists (GSBR-1290) for obesity and diabetes. Comparable as an emerging obesity-focused biotech with differentiated mechanism (oral vs. injectable) addressing adherence.
  • Zealand Pharma: Clinical-stage biotech developing petrelintide (amylin analog) for obesity, with major partnership with Boehringer Ingelheim. Comparable through its amylin-focused obesity pipeline, mirroring Metsera's amylin program strategy.
  • Altimmune: Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity in Phase 2. Comparable as a smaller-cap, clinical-stage obesity biotech pursuing differentiated incretin mechanisms.
  • Carmot Therapeutics: Clinical-stage biotech developing incretin-based obesity therapies (acquired by Roche in 2024). Comparable as a clinical-stage biotech with differentiated GLP-1 assets that was acquired by a major pharma for its obesity pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Metsera social profiles

Digital presence

Metsera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Metsera leadership team

Management profile

Number of profiles

Metsera funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Metsera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metsera

What does Metsera do?

Metsera is a clinical-stage biopharmaceutical company developing a portfolio of novel injectable and oral hormone-based therapies (GLP-1 receptor agonists and amylin analogs) for obesity and metabolic diseases. Its pipeline includes late-stage candidates aimed at next-generation obesity treatment through ultra-long-acting peptides and oral formulations.

Is Metsera a public or private company?

Metsera is a private company. It is classified as corporate owned and is currently acquired.

When was Metsera founded?

Metsera was founded in 2024. It employs 51 to 100 people.

Where is Metsera based?

Metsera is headquartered in New York, United States, in the North America region.

How does Metsera make money?

One revenue line is on record: R&D Pipeline Development.

Who are Metsera's main competitors?

Viking Therapeutics is listed as a direct peer. Broad incumbents are Eli Lilly, Novo Nordisk, Amgen, AstraZeneca and Roche. Emerging players are Structure Therapeutics, Zealand Pharma, Altimmune and Carmot Therapeutics.

Does Metsera have an API?

No public API is recorded for Metsera.

What industry is Metsera in?

Metsera's product category is Obesity Therapeutics. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies, with a secondary code of HLAKADAN, Endocrine Hypertension & Neuroendocrine Disorders.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StWhat Is Pfizer (PFE) Asking Of Its $10 Billion Metsera Bet?Pfizer agreed to acquire obesity drug developer Metsera for about $10 billion in cash, expanding its metabolic disease portfolio. The deal strengthens Pfizer's push into anti-obesity treatments, a segment forecast to reach roughly $65 billion in annual sales by 2035. CEO Albert Bourla expects Chinese biopharma companies to become Pfizer's main competitors by 2030.TradingViewNews by Dow Jones Newswires on TradingView, 2026-09-26Biotech stocks surged this year, with IBB up 24% and XBI up 28%, driven by therapeutic breakthroughs and M&A. Panelists expect continued M&A and AI-driven drug discovery, while noting tech sector rotation risks. Upcoming trial readouts include Librexia-AF and Summit's HARMONi-3.TipranksThe Second Act of BiotechPfizer acquired Metsera for $7B to advance berobenatide, an ultra-long-acting GLP-1 agonist showing up to 12.3% weight loss in Phase 2b. Moderna's Phase 3 melanoma study met key endpoints for its personalized mRNA cancer therapy. Both face execution risks: Pfizer must prove Phase 3 competitiveness, Moderna needs regulatory approval and scalable manufacturing.pharmaphorumPfizer targets $2.5bn more in cost savingsPfizer announced an additional $2.5 billion in cost-cutting initiatives, bringing its three-year target above $10 billion. The savings, realized 2027-2029, come as Q2 sales grew 1% to $15 billion, driven by Eliquis. The company predicts 2025 sales of $60.5-62.5 billion and growth from 2028.BNNPfizer beats earnings estimates, targets US$2.5 billion in additional cost cutsPfizer reported better-than-expected Q2 earnings, driven by Eliquis and Padcev sales, and announced $2.5 billion in additional cost cuts. The company expects $9.7 billion in total savings through 2029 and raised its full-year sales forecast to $60.5–62.5 billion. It plans to maintain its dividend and resume increases after patent expirations.FierceBiotechPfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearoutPfizer has discontinued two clinical-stage obesity programs—MET-224o, a GLP-1 receptor agonist acquired from Metsera for $10 billion, and PF-07976016, a GIPR antagonist in phase 2 development—as part of its quarterly R&D pipeline update. The terminations leave Pfizer with only one oral GLP-1 drug (PF-08642534, also known as YP05002 licensed from YaoPharma) while the company shifts focus to its phase 3 injectable candidate berobenatide. Pfizer also discontinued two additional assets: PF-07258669, an MC4R antagonist for malnutrition partnered with Nxera Pharma, and PF-07985631 for nephropathy.Tech TimesPfizer Q2 2026 Earnings Beat Estimates; Non-COVID Revenue Surges 18% OperationallyPfizer reported Q2 2026 revenue of $15.03 billion, beating estimates, and adjusted EPS of $0.77, nine cents above consensus. Non-COVID launched products grew 18% operationally, while COVID products fell 34-95%. The company raised its full-year revenue guidance midpoint by $500 million to $61.5 billion.BNNPfizer beats earnings estimates, targets US$2.5 billion in additional cost cutsPfizer reported better-than-expected Q2 results, driven by strong Eliquis and Padcev sales, and announced $2.5 billion in additional cost cuts. The company expects $9.7 billion in total savings through 2029 and raised its full-year sales forecast to $60.5–62.5 billion. It plans to return to stronger growth after 2028.BenzingaWhat's Going on With Pfizer Stock Tuesday? - Pfizer (NYSE:PFE)Pfizer reported adjusted EPS of 77 cents, beating the 69-cent estimate, and raised its fiscal 2026 revenue guidance to $60.5–62.5 billion. The company also affirmed its earnings guidance and saw shares rise 2.14% to $25.56.Endpoints NewsExclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts nearVerdiva Bio, a biotech developing a long-acting obesity pill, has hired Steve Marso, former chief medical officer at Metsera, as its new CMO. Marso brings experience from a biotech working on similar GLP-1 related technology, filling a key leadership role as the company approaches crucial clinical readouts.